Home » Newsletters » BioWorld Science

BioWorld Science

July 21, 2003

View Archived Issues

Disappointing results for proof-of concept trial of VI-0162 in PE

Good safety and pharmacokinetic profile reported for rhFXIII in healthy volunteers

Esperion updates clinical development progress

Tularik highlights Q2 achievements

Oral direct thrombin inhibitors for the prevention of thrombosis after hip replacement surgery

Keppra oral solution approved for epilepsy

Synergistic prevention of arterial thrombosis reported for aspirin and CS-747 in preclinical studies

ArQule signs agreement to acquire Cyclis

Three related series of PPARalpha agonists patented by AstraZeneca researchers

Novel CCR4 receptor modulators for asthma therapy under study at AstraZeneca

New metabolically stable antiandrogens prepared and tested at Chugai

Lundbeck presents new NK2 antagonists with utility in psychiatric disorders

Kyowa Hakko and Fuji researchers identify 1,3,4-thiadiazole-based antitumor agents

Novel FTase inhibitors in early development at Janssen

AstraZeneca presents novel analgesic bradykinin B2 antagonists

Zentaris prepares and tests new GnRH antagonists

Potential role suggested for LB-30870 in the prophylaxis and prevention of thrombosis

Orally active taxane derivative MAC-321 demonstrates broad therapeutic potential

Antiangiogenic MMP inhibitor designed at Kolon

Early completion anticipated for pivotal R-1549 trial

Promising preclinical data reported for novel histone deacetylase inhibitor

Topamax safety information updated

BTG to evaluate BGC-9331 as a first-line treatment for gastric cancer

New low doses of Premarin approved for prevention of postmenopausal osteoporosis

Selective CDK inhibitor JNJ-7706621 as potential antitumor development candidate

Ansamycin-based Hsp90 inhibitor characterized by Conforma at AACR meeting

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Laigo raises €11.5M seed money for targeted protein degradation
BioWorld Science
Laigo Bio BV has raised €11.5 million (US$13.7 million) in a seed round for the further development of a new approach to inducing targeted protein degradation by...